Precision management of cenobamate in drug-resistant epilepsy: integrating pharmacogenetics, therapeutic drug monitoring, and real-world clinical strategies
Frontiers in Pharmacology · 04.06.2026 · 17
DOI: 10.3389/fphar.2026.1830217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.06.2026. Verfasst von Giuseppe d'Orsi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Unit - Epilepsy Center, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotond, Italy. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cenobamate (CNB) demonstrates high efficacy in drug-resistant focal epilepsy, yet optimal management requires personalized strategies. This exploratory case series describes five patients selected from a cohort of 125 individuals treated with CNB, examining the relationship between pharmacogenetic (PGx) profiles and clinical outcomes. Clinical data and therapeutic drug monitoring (TDM) were integrated with targeted Next-Generation Sequencing of key metabolic genes (UGT2B7, UGT2B4, CYP2E1, CYP2B6, CYP2A6, CYP3A4, CYP2C19) to predict metabolizer phenotypes. Three patients (Cases 1, 3, 4) achieved seizure freedom or ≥50% response at sub-target or target doses (100–200 mg/day ) enabling early de-escalation of concomitant sodium channel blockers and valproate. This success was supported by a proactive digital communication protocol and a mandatory 100 mg clinical checkpoint. Case 2—a non-responder at 400 mg/day despite therapeutic plasma levels (28.22 mg/L)—exhibited a predicted “Ultrarapid Metabolizer” (UM) phenotype characterized by UGT2B7 Haplotype 4 and CYP2E1 duplication, suggesting possible pharmacokinetic contribution to non-response. Case 5 experienced dose-limiting toxicity at 100 mg/day; we hypothesized this toxicity could be driven by a drug-drug-gene interaction involving CNB-mediated CYP2C19 inhibition that impairs clearance of N-desmethylclobazam (the active metabolite of clobazam) in a patient with impaired CYP2A6 activity and intermediate UGT2B7 function. As an exploratory case series, these findings require validation in adequately powered prospective studies. Associations between UM phenotype and non-response, and between PM phenotype and dose-limiting toxicity, represent preliminary observations that may reflect pharmacokinetic variability. Nevertheless, our experience is consistent with a personalized, sub-target dose titration strategy that may help minimize adverse events in complex polypharmacy settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neurology Unit - Epilepsy Center, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotond, Italy.
- Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analyses, IRCCS Istituto Giannina Gaslini, Genova, Italy.
- Department of Pharmacy - Drug Sciences, University of Bari "Aldo Moro", Bari, Italy.
- Medicina Trasfusionale e Laboratorio Analisi, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy.
- UOC Genetica Medica, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy.
Zitieren
APA
d'Orsi, G., Di Claudio, M. T., Cafaro, A., Barco, S., Robustella, M., Locatelli, N., Liantonio, A., Imbrici, P., Ciavarella, G., Rinaldi, A., Fania, G., Costantino, U., Carella, M., Cangemi, G., & Miscio, G. (2026). Precision management of cenobamate in drug-resistant epilepsy: integrating pharmacogenetics, therapeutic drug monitoring, and real-world clinical strategies. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1830217
Vancouver
d'Orsi G, Di Claudio MT, Cafaro A, Barco S, Robustella M, Locatelli N, et al. Precision management of cenobamate in drug-resistant epilepsy: integrating pharmacogenetics, therapeutic drug monitoring, and real-world clinical strategies. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1830217
BibTeX
@article{dOrsi2026,
author = {d'Orsi, Giuseppe and Di Claudio, Maria Teresa and Cafaro, Alessia and Barco, Sebastiano and Robustella, Marta and Locatelli, Nicolò and Liantonio, Antonella and Imbrici, Paola and Ciavarella, Grazia and Rinaldi, Antonio and Fania, Giuseppe and Costantino, Umberto and Carella, Massimo and Cangemi, Giuliana and Miscio, Giuseppe},
title = {Precision management of cenobamate in drug-resistant epilepsy: integrating pharmacogenetics, therapeutic drug monitoring, and real-world clinical strategies},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1830217}
}
EUVIMED